Results (3632)
Review will look into risk of agranulocytosis, a sudden drop in white blood cells that can lead to serious infections, and measures to minimise it.
Start of review of painkiller metamizole and risk of secondary cancers with CAR T-cell medicines.
![Management Board June 2024](https://www.ema.europa.eu/sites/default/files/2024-06/2024_ManagementBoard-3-_WEB-square_v1.png)
Board adopts Executive Director’s annual activity report for 2023 and hears updates on implementation of new fee regulation.
![A doctor and a patient looking at a screen](https://www.ema.europa.eu/sites/default/files/2024-06/2024-6_ACT%20EU%20pilots_WEB_square.png)
Pilots are part of ACT EU collaboration to foster high-quality clinical research in the EU.
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
![medicine pills and tablets](https://www.ema.europa.eu/sites/default/files/2023-11/Web%20image_CHMP_standard_square.png)
EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its May 2024 meeting
Ixchiq was assessed under the OPEN framework to promote global public health
Durveqtix received support through the PRIority Medicines (PRIME) scheme due to its potential to improve patients’ quality of life
![Annual report 2023 formats](https://www.ema.europa.eu/sites/default/files/2024-05/2024-05_Annual-report-2023-3-_digital_WEB_square%20%281%29.png)
EMA publishes 2023 annual report
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.